Prelude Therapeutics Incorporated logo

Prelude Therapeutics Incorporated

NASDAQ:PRLD

Overview | Financials
Company Name Prelude Therapeutics Incorporated
Symbol PRLD
Currency USD
Price 1.02
Market Cap 56,135,869
Dividend Yield 0%
52-week-range 0.797 - 6.8
Industry Biotechnology
Sector Healthcare
CEO Dr. Krishna Vaddi D.V.M., Ph.D.
Website https://www.preludetx.com

An error occurred while fetching data.

About Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in

Related Stocks

bluebird bio, Inc. logo

bluebird bio, Inc.

BLUE

8.01 USD

VistaGen Therapeutics, Inc. logo

VistaGen Therapeutics, Inc.

VTGN

2.84 USD

Singular Genomics Systems, Inc. logo

Singular Genomics Systems, Inc.

OMIC

19.8 USD

KalVista Pharmaceuticals, Inc. logo

KalVista Pharmaceuticals, Inc.

KALV

7.4 USD

Cogent Biosciences, Inc. logo

Cogent Biosciences, Inc.

COGT

7.37 USD

PepGen Inc. logo

PepGen Inc.

PEPG

2.72 USD

VBI Vaccines Inc. logo

VBI Vaccines Inc.

VBIV

0.065 USD

Zentek Ltd. logo

Zentek Ltd.

ZTEK

1.25 USD

Sutro Biopharma, Inc. logo

Sutro Biopharma, Inc.

STRO

1.72 USD

Viemed Healthcare, Inc. logo

Viemed Healthcare, Inc.

VMD

8 USD

Financials

Numbers are in millions USD

Numbers are in millions USD